argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
18 sep 2014 - 07:04
Statutaire naam
argenx SE
Titel
arGEN-X completes recruitment of first cohort of 15 patients with CD70-positive solid tumors into its Phase 1b expansion trial with ARGX-110
Bericht
18 September 2014
Breda, the Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, has completed enrolment of a first cohort of 15 patients with CD70-positive solid tumors into an open-label Phase 1b expansion trial with ARGX-110, a novel anti-CD70 therapeutic antibody. Recruitment of a second cohort of 15 patients with CD70-positive hematological malignancies is ongoing. The primary objective of the expansion trial is to select one or more indications to take forward into further clinical trials.
"We have seen favorable safety profiles, as well as encouraging initial signs of efficacy from the dose escalation portion of the study of ARGX-110 in both solid and hematological tumors. Based on these initial results, we have focused enrollment of the expansion phase on CD70-positive patients with those histologies that have shown biological activity to date," commented Alain Thibault, Chief Medical Officer of arGEN-X. "Enrollment of the second cohort of 15 patients with CD70-positive hematological malignancies is ongoing. We expect to report topline results from the expansion phase of the trial and select indications for further clinical studies in the second half of 2015."
In the init
Gerelateerde downloads
Datum laatste update: 25 februari 2026